Does the CYP1B1 rs1056836 variant shift estradiol metabolism toward reactive catechol estrogens?

The CYP1B1 rs1056836 polymorphism is a well-characterized genetic variation that significantly alters the metabolic profile of estradiol, favoring the production of potentially genotoxic metabolites.

Clinical and metabolic evidence

The rs1056836 polymorphism, a G→C transversion resulting in a valine-to-leucine substitution at codon 432 (Val432Leu), serves as a primary driver of metabolic flux in human estrogen processing.

• Increased Catalytic Efficiency: Experimental kinetic studies demonstrate that the Leu432 variant (C allele) exhibits significantly higher catalytic efficiency for the 4-hydroxylation pathway compared to the Val432 variant.
• Altered Estrogen Levels: Because this variant accelerates estrogen catabolism, carriers often exhibit lower circulating estradiol concentrations. Clinical observations have linked this "metabolic drain" to lower bone mineral density and altered risks for hormone-sensitive tissues, particularly in premenopausal individuals.

Mechanistic explanations

The shift toward 4-hydroxylation is biologically significant because it moves estradiol metabolism away from more stable pathways and toward the production of reactive catechol estrogens.

• Formation of 4-OHE2: The primary product of this enzymatic shift is 4-hydroxyestradiol (4-OHE2). Unlike its 2-hydroxy counterpart, 4-OHE2 is highly prone to oxidation, forming electrophilic estradiol-3,4-quinones.
• Genotoxic Pathways: These quinone metabolites are potent DNA-damaging agents. They form depurinating DNA adducts (specifically at N7-guanine and N3-adenine sites), which destabilize the DNA backbone and may initiate mutagenic events.
• Oxidative Stress: These reactive catechols participate in redox cycling, a process that consumes NADPH and generates reactive oxygen species (ROS), such as superoxide anions. This leads to secondary oxidative damage, evidenced by increased markers like 8-hydroxy-2'-deoxyguanosine (8-OHdG).

Bottom line

The CYP1B1 rs1056836 polymorphism effectively shifts estrogen metabolism toward the 4-hydroxylation pathway, increasing the production of 4-OHE2 and reactive quinones that promote DNA damage and oxidative stress. This genetic variant is a key factor in determining an individual's "metabolic fingerprint" of estrogen exposure.